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ORIGINAL ARTICLE BACTERIOLOGYIs the prevalence of antibiotic-resistant organisms changing in Canadian
hospitals? Comparison of point-prevalence survey results in 2010 and 2012V. Williams1, A. E. Simor1, A. Kiss2, A. McGeer3, Z. Hirji4, O. E. Larios5, C. Moore3 and K. Weiss6 for Infection Prevention and
Control—Canada
1) Sunnybrook Health Sciences Centre, 2) Institute of Clinical Evaluative Sciences, 3) Mount Sinai Hospital, 4) The Scarborough Hospital, Toronto,
Ontario, 5) University of Calgary, Calgary, Alberta and 6) Hôpital Maisonneuve-Rosemont, Montreal, Quebec, CanadaAbstractA national point-prevalence survey for infection or colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus (VRE), and for Clostridium difﬁcile infection (CDI) was done in Canadian hospitals in 2010. A follow-up survey was done in November
2012 to determine whether there were any changes in the prevalence of these organisms; we also determined the prevalence of extended-
spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae (CREs). Associations between
prevalence and infection prevention and control policies were evaluated in logistic regression models. A total of 143 (67% of eligible facilities)
hospitals with 29 042 adult inpatients participated in the survey, with representation from all 10 provinces; 132 hospitals participated in 2010
and 2012. There were no signiﬁcant changes in the median prevalence of MRSA in 2010 (4.3%) compared to 2012 (3.9%), or of CDI in 2010
(0.8%) compared to 2012 (0.9%). A higher median prevalence of VRE was identiﬁed in 2012 (1.3%) compared to 2010 (0.5%) (p 0.04), despite
decreased VRE screening in 2012. The median prevalence of ESBLs was 0.7% and was 0 for CREs; CREs were reported from only 10 hospitals
(7.0%). A policy of routinely caring for patients with MRSA or VRE in a private isolation room was associated with lower prevalence of these
organisms. Targeted screening of high-risk patients at admission was associated with lower MRSA prevalence; better hand hygiene compliance
was associated with lower VRE prevalence. These data provide national prevalence rates for antibiotic-resistant organisms among adults
hospitalized in Canadian hospitals. Certain infection prevention and control policies were associated with prevalence.
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E-mail: andrew.simor@sunnybrook.caIntroductionProspective national surveillance for antibiotic-resistant organ-
isms (AROs) in Canada has been conducted by the Canadian
Nosocomial Infection Surveillance Program since 1995 [1–4].
Although the surveillance provides important incidence data, it isClinical Microbiology and Infection © 2015 European Society of Climited in that only a relatively small number of hospitals, pre-
dominantly tertiary-care teaching facilities, participate. In 2010,
we conducted the ﬁrst national prevalence survey of AROs,
including methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus (VRE), and Clostridium difﬁcile
infection (CDI), in a large and representative sample of Canadian
hospitals [5]. However, as the epidemiology of these organisms
continues to evolve, it is important to monitor changes that may
occur over time. Therefore, we conducted a follow-up point-
prevalence survey in Canadian hospitals in 2012, this time
expanding the survey to also include information regarding
extended-spectrum β-lactamase (ESBL)-producing organisms and
carbapenem-resistant Enterobacteriaceae (CREs). We alsoClin Microbiol Infect 2015; 21: 553–559
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.01.024
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and control policies associated with the prevalence of AROs.Materials and methodsTABLE 1. Characteristics of participating Canadian hospitals
in 2010 and 2012
Hospital characteristic 2010, n (%) 2012, n (%)
Regiona
Eastern Canada 26 (15) 24 (17)
Central Canada 103 (58) 88 (61)
Western Canada 47 (27) 31 (22)
Size
200 beds 92 (52) 79 (55)
201–500 beds 74 (42) 58 (41)
>500 beds 10 (6) 6 (4)
Type
Teaching 55 (31) 45 (31)
Nonteaching 121(69) 98 (69)
aRegions are as follows: Eastern Canada, Newfoundland and Labrador, Prince
Edward Island, Nova Scotia and New Brunswick; Central Canada, Quebec and
Ontario; and Western Canada, Manitoba, Saskatchewan, Alberta, British Columbia
and the Northwest Territories.Study design and study participants
The methods and study deﬁnitions used in this survey were
similar to those described for the survey done in 2010 [5]. All
acute-care hospitals in Canada with at least 50 inpatient beds
for adults were invited to participate. Hospitals providing only
pediatric, rehabilitation, psychiatric, or long-term care were
excluded. Participating hospitals were asked to select one
weekday between 5 November and 16 November 2012 on
which to conduct the survey. On the survey date, all adult (18
years of age) inpatients were identiﬁed by the hospital census,
and those colonized or infected with MRSA, VRE, ESBL or CRE,
or who had CDI were determined using hospital infection
prevention and control and laboratory databases. Medical re-
cords were reviewed to determine whether the patient met
criteria for infection, and whether the ARO was healthcare or
community associated. A standardized questionnaire describing
hospital characteristics (size, type of facility, scope of medical
services provided and laboratory facilities for ARO detection),
and the facilities’ infection prevention and control policies
regarding AROs was completed. Infection control professionals
at the participating hospitals received standardized webinar
training for data collection. The Ethics Review Board at Sun-
nybrook Health Sciences Centre (Toronto, Ontario) approved
the conduct of this study.
Study deﬁnitions
At the time of the survey, it was a standard practice in Canadian
hospitals for patients colonized or infected with any one of the
target AROs to be cared for with additional infection control
precautions (contact isolation). Therefore, patients with MRSA,
VRE, ESBL or CRE were deﬁned as those who were on addi-
tional precautions for any of these organisms on the day of the
survey and who had had a culture conﬁrming the presence of
the organism obtained on that day or any time previously. Pa-
tients were determined to have an infection caused by these
organisms if they met National Healthcare Safety Network
criteria [6]. CDI was diagnosed in the presence of diarrhea
(three or more watery stools within 24 hours) with a positive
C. difﬁcile toxin assay, and receipt of treatment for this with
either metronidazole or oral vancomycin on the day of the
survey, or if pseudomembranous colitis had been documented
by endoscopy within the previous 14 days [2]. MRSA, VRE and
CDI were determined to be community or healthcare associ-
ated using standard criteria [1,2,5].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectData analysis and statistical methods
The primary outcomes were the prevalence of each of the
AROs, calculated as the number of cases per 100 adult in-
patients in each of the participating hospitals on the survey date.
For each ARO, the median prevalence in 2010 and 2012 was
compared by the Mann-Whitney U test. In order to describe
institutional characteristics and policies associated with preva-
lence, multivariable logistic regression models were run using
sets of variables that had been selected a priori. Before
modelling, the set of variables were assessed for multi-
collinearity using tolerance statistics. If the tolerance statistic
was less than 0.4, only one member of a correlated set of
variables was retained for the multivariable model. Estimates
from the model were displayed using odds ratios and their
associated 95% conﬁdence intervals. Two-tailed p values less
than 0.05 were considered to be signiﬁcant. All analyses were
carried out by SAS version 9.3 (SAS Institute, Cary, NC, USA).ResultsA total of 143 hospitals (representing 67% of eligible facilities)
with 30 609 acute-care beds (69% of eligible inpatient beds)
participated in the survey and submitted data in 2012 (132
hospitals participated in both 2010 and 2012). There was
participation from all 10 Canadian provinces, with 45 teaching
hospitals (31%). There were 79 hospitals (55%) with fewer than
200 beds, and six (4%) with more than 500 beds. The
geographic distribution, hospital size and proportion of teaching
hospitals participating in 2012 did not differ from those
participating in 2010 (Table 1) [5].
Participating hospitals reported a total of 2533 (8.7 per 100
inpatients; 95% conﬁdence interval (CI), 8.4–9.1) patients with
at least one of the targeted AROs: 1308 (4.5/100 inpatients;
95% CI, 4.3–4.8) colonized or infected with MRSA, 190 (0.7/ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 553–559
CMI Williams et al. Prevalence of antibiotic-resistant organisms 555100 inpatients; 95% CI, 0.6–0.8) with MRSA infection, 779 (2.7/
100 inpatients; 95% CI, 2.5–2.9) colonized or infected with
VRE, 410 (1.4/100 inpatients; 95% CI, 1.3–1.6) with CDI, 362
(1.3/100 inpatients; 95% CI, 1.1–1.4) colonized or infected with
an ESBL-producing organism and 32 (0.1/100 inpatients; 95%
CI, 0.08–0.16) colonized or infected with a CRE. Most (55%) of
the carbapenemases identiﬁed were Klebsiella pneumoniae car-
bapenemase; others included OXA-48 (20%) and NDM-1
(15%). There were 292 patients (11.5%) concurrently infected
or colonized with two or more of the AROs. MRSA, CDI and
VRE were most often healthcare associated, and were thought
to have been community-acquired in 29.9%, 22.7% and 5.6% of
patients, respectively. Few patients were identiﬁed with VRE or
CRE infections. Patients with MRSA were reported from almost
all hospitals (93.7%); patients with VRE were reported in 97
hospitals (67.8%), CDI in 96 (67.1%), ESBLs in 71 (49.7%) and
CRE in only 10 (7.0%). Although the prevalence of MRSA did
not differ by region of the country, the prevalence of VRE
colonization or infection was lower in eastern Canada
compared to the rest of the country (median prevalence 0 per
100 inpatients vs. 1.9 and 1.3 in central and western Canada,
respectively; p 0.001) (Fig. 1). The central region of Canada had
a higher prevalence of CDI (1.4 per 100 inpatients vs. 0.4 in
eastern and western Canada; p < 0.001).
The mean and median prevalence of the AROs reported in
2010 and 2012 from the 132 hospitals that participated in both
surveys are summarized in Table 2. There were no signiﬁcant
changes in the prevalence of MRSA or CDI, but a higherFIG. 1. Median (range) prevalence
(per 100 inpatients) of methicillin-
resistant Staphylococcus aureus
(MRSA), vancomycin-resistant Entero-
coccus (VRE), extended-spectrum
β-lactamase (ESBL)-producing Enter-
obacteriaceae, carbapenem-resistant
Enterobacteriaceae (CRE) and Clos-
tridium difﬁcile infection (CDI) in
Canada, 2012.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyprevalence of VRE colonization and infection was identiﬁed in
2012 (median 1.3 per 100 inpatients) compared to 2010 (0.5
per 100 inpatients; p 0.04).
In 2010 and 2012, all participating hospitals conducted either
universal or targeted active surveillance for MRSA colonization
and infection. However, screening for VRE colonization
decreased from almost all hospitals (99.4%) in 2010 to 128
hospitals (89.5%) in 2012 (p < 0.001), and a minority of hos-
pitals conducted active surveillance for ESBLs (32%) or CREs
(32%). The proportion of hospitals using a PCR assay for
detection of C. difﬁcile toxin genes increased from 9% in 2010 to
48% in 2012. Institutional characteristics and hospital infection
prevention and control policies associated with MRSA, VRE and
CDI prevalence in 2012 are summarized in Table 3. Teaching
hospitals had higher prevalence of CDI, whereas hospitals with
solid organ transplant units had higher prevalence of VRE.
Several infection control policies including ARO screening of
high-risk patients, use of private isolation rooms, routine pro-
vision of MRSA decolonization, measures of hand hygiene
compliance and enhanced environmental cleaning were found
to be associated with prevalence.DiscussionDespite ongoing concerns that antibiotic resistance is an
increasing public health threat globally, the epidemiology and
outcomes associated with AROs in healthcare settings remainand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 553–559
TABLE 2. Mean and median prevalence of selected antimicrobial-resistant organisms in adult inpatients of Canadian acute-care
hospitals, 2010 and 2012
Organism
2010 Prevalence (per 100 inpatients) 2012 Prevalence (per 100 inpatients)
pan Mean (SD) Median (range) n Mean (SD) Median (range)
MRSA
Colonization or infection 1472 5.1 (4.0) 4.3 (0–22.1) 1218 4.8 (3.8) 3.9 (0.-26.8) 0.81
Infection 175 0.6 (0.9) 0.3 (0–5.9) 170 0.7 (0.9) 0.3 (0–4.9) 0.78
VRE
Colonization or infection 557 1.7 (2.7) 0.5 (0–13.0) 738 2.3 (3.2) 1.3 (0–18.0) 0.04
Infection 11 0.05 (0.2) 0 (0–1.8) 18 0.06 (0.2) 0 (0–1.5) 0.28
CDI 350 1.1 (1.2) 0.8 (0–8.6) 386 1.2 (1.2) 0.9 (0–5.5) 0.29
ESBL
Colonization or infection Not measured 345 1.4 (2.2) 0.7 (0–13.5)
Infection Not measured 97 0.4 (0.7) 0 (0–4.0)
CRE
Colonization or infection Not measured 32 0.07 (0.3) 0 (0–3.0)
Infection Not measured 12 0.03 (0.2) 0 (0–1.3)
CDI, Clostridium difﬁcile infection; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase-producing Enterobacteriaceae; MRSA, methicillin-resistant
Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus.
aComparing median prevalence in 2010 with that in 2012.
556 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIpoorly understood, largely because few countries have robust
or comprehensive surveillance programs in place (http://
www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-
threats-2013-508.pdf; http://www.who.int/drugresistance/
documents/surveillancereport/en/). National surveillance for
AROs in Canada has been conducted by the Canadian Noso-
comial Infection Surveillance Program, providing incidence data
[1–4], but the number of participating hospitals is relatively
small. Prevalence surveys can provide a snapshot of the burden
of disease associated with AROs and may permit a larger and
more representative sample of hospitals to participate. This
point-prevalence survey determined that approximately one in
11 hospitalized adults in Canada was colonized or infected withTABLE 3. Covariates associated with infection prevalence in multiv
Covariates
MRSA colonization/infection MRSA infection
OR (95% CI) p OR (95% CI)
Occupancy rate 1.00 (0.99–1.01) 0.90 1.01 (1.00–1.03)
Teaching hospital 0.99 (0.86–1.14) 0.91 0.82 (0.58–1.17)
Inpatient pediatrics 0.85 (0.74–0.98) 0.03 1.02 (0.71–1.45)
Solid organ transplant unit
Targeted admission screeninga 0.75 (0.65–0.86) <0.001 1.14 (0.80–1.63)
ICU admission screening 1.01 (0.88–1.16) 0.85 0.93 (0.67–1.30)
Nasal + extranasal screening 1.34 (0.89–2.01) 0.16 3.52 (0.47–26.58)
Routine use of private room 0.74 (0.64–0.86) <0.001 0.42 (0.28–0.64)
Routine use of surgical mask 0.75 (0.61–0.92) 0.006 0.92 (0.55–1.56)
Routine use of antiseptic soapb 1.13 (0.97–1.32) 0.13 1.38 (0.94–2.03)
Routine MRSA decolonizationc 0.59 (0.48–0.73) <0.001 0.77 (0.44–1.35)
Enhanced environmental cleaning 0.82 (0.72–0.93) 0.001 0.96 (0.70–1.31)
Hand hygiene compliance >80% 0.92 (0.80–1.06) 0.26 0.92 (0.64–1.33)
>200 hand hygiene opportunities
audited per unit per year
1.04 (0.91–1.18) 0.60 1.00 (0.71–1.42)
Turnaround time <24 hours for
receipt of C. difﬁcile laboratory
test results
Not all covariates were tested in all of the models; results presented for the covariates incl
CDI Clostridium difﬁcile infection; CI, conﬁdence interval; ICU, intensive care unit; MRSA, me
Enterococcus.
aTargeted screening for MRSA or VRE at admission to hospital on the basis of risk factor as
bDaily bathing/washing of infected or colonized patient using antiseptic soap, such as chlorhe
cMRSA decolonization, with intranasal mupirocin with or without use of other topical or sy
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectone of the targeted AROs. With approximately 36 776 acute-
care beds, and 93% bed occupancy rates in Canadian hospi-
tals (http://www.oecd.org/health/healthdata), this would corre-
spond to at least 2976 hospitalized patients with an ARO in
Canada on any given day. This is an underestimate, as other
signiﬁcant resistant phenotypes were not included in the
survey.
As observed in other parts of the world, the single most
common ARO identiﬁed in the point-prevalence survey as
causing infection in Canadian hospitals was C. difﬁcile [7,8].
C. difﬁcile has also been reported to be the most common
bacterial pathogen associated with infection outbreaks in
healthcare facilities [9]. Recently in Canada there has been aariate models
VRE colonization/infection CDI
p OR (95% CI) p OR (95% CI) p
0.08 0.99 (0.98–1.00) 0.02 1.01 (0.99–1.01) 0.19
0.27 1.13 (0.95–1.35) 0.16 1.26 (1.02–1.55) 0.03
0.93
1.31 (1.06–1.63) 0.01
0.47 1.03 (0.87–1.23) 0.73
0.68 1.75 (1.46–2.11) <0.001
0.22
<0.001 0.42 (0.36–0.50) <0.001 0.86 (0.68–1.09) 0.22
0.76
0.10
0.36
0.78 0.86 (0.67–1.10) 0.22
0.66 0.72 (0.59–0.88) 0.002 1.12 (0.89–1.41) 0.35
0.99 0.76 (0.64–0.89) <0.001 1.21 (0.96–1.52) 0.10
1.42 (1.08–1.85) 0.01
uded in each model.
thicillin-resistant Staphylococcus aureus; OR, odds ratio; VRE, vancomycin-resistant
sessment.
xidine gluconate.
stemic agents.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 553–559
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patients from 6.8/10 000 patient-days in 2007 to 6.0/10 000
patient-days in 2012 (p < 0.001) [10]. The CDI prevalence in
our study did not change in 2012 compared to that found in
2010, and was similar (mean 1.2/100 inpatients) to that re-
ported in national surveillance done in the United States (1.3/
100 patients), the United Kingdom (1.7/100 inpatients), and
Germany (1.3/100 patients) [11–13].
The prevalence of MRSA in Canadian hospitals did not
substantially change between 2010 and 2012, and a relatively
small proportion of patients (15%) had MRSA infection, rep-
resenting a mean MRSA infection prevalence of 0.7/100 in-
patients. Although the incidence of invasive healthcare-
associated MRSA infections has been decreasing in the United
States [14], the recently reported prevalence of MRSA in-
fections in US hospitals (2.5 per 100 patients) [15] is higher than
that observed in the current study. The prevalence of MRSA in
European hospitals varies considerably, and has ranged from
less than 1% (in the Netherlands) to 24% in certain patient
populations in British hospitals [16–18]. Some of this variability
is likely related to regional and national differences in the
implementation of infection prevention and control
interventions.
The proportion of Enterococcus faecium isolates resistant to
glycopeptides varies considerably across Europe, but has
increased recently in a few countries [17,19], and VRE are
endemic in many US facilities [20]. We found that the preva-
lence of VRE-colonized patients has increased signiﬁcantly in
Canadian hospitals, despite the fact that in 2012 fewer hospitals
were conducting active surveillance for this organism. These
data suggest increasing VRE transmission in hospitals in Canada,
but to date there has been no apparent increase in VRE
infection rates, and the number of VRE infections identiﬁed in
Canadian hospitals remains generally low [4].
This study is the ﬁrst to provide national prevalence results
for multi-drug-resistant Gram-negative organisms such as
ESBLs and CREs in Canadian hospitals. Detection of ESBL
colonization is dependent on screening protocols, which were
routinely used in only one-third of Canadian hospitals. There-
fore, the observed prevalence in this study is likely an under-
estimate. However, the ESBL infection rate (not subject to the
same detection bias) appeared to be relatively low (mean 0.4
per 100 inpatients). There are few comparable data from other
countries, but the mean ESBL colonization/infection prevalence
in this study (1.4 per 100 inpatients) was similar to that recently
reported in German hospitals (1.2%) [13]. Rising CRE rates
have been recently reported from many countries [21–23]. In
2012, 4.6% of US hospitals reported at least one CRE-related
healthcare-associated infection, and the proportion of Enter-
obacteriaceae that were carbapenem resistant increased fromClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology1.2% in 2001 to 4.2% in 2011 [21]. In Europe, 20 countries
reported one or more invasive K. pneumoniae isolate resistant
to carbapenems in 2012, and these organisms appear to have
become endemic in certain countries [22,23]. Carbapenemase-
producing organisms were rarely identiﬁed in Canadian hospi-
tals before 2010 [3]. Patients with CRE infection or coloniza-
tion (predominantly K. pneumoniae carbapenemase, OXA-48
and NDM-1) were also infrequently identiﬁed in the current
survey, and were reported from only 10 hospitals (7%).
A secondary objective of this study was to identify insti-
tutional characteristics or policies associated with prevalence
of MRSA, VRE and CDI. As reported in our 2010 survey, a
policy of routinely placing patients colonized or infected with
MRSA or VRE into a private room was associated with a
lower prevalence of these organisms [5]. Pre-emptive isola-
tion of high-risk patients was associated with lower rates of
MRSA bloodstream infections in Europe [24], but with high
occupancy rates (generally >92%), this approach is not often
feasible in Canadian hospitals. Targeted screening of high-risk
patients at admission and MRSA decolonization were asso-
ciated with lower MRSA prevalence, whereas more frequent
hand hygiene audits and higher hand hygiene compliance were
associated with lower VRE prevalence. In univariate analyses,
hospitals with a greater number of full-time-equivalent
infection control professionals per 100 inpatient beds had
lower VRE prevalence (unadjusted odds ratio 0.58, 95% CI
0.50–0.67), but there was no such association with MRSA or
CDI prevalence (Appendix 1, available online). As anticipated,
hospitals that conducted periodic prevalence screening of
inpatient units for MRSA or VRE had higher rates of these
organisms. These variables were not included in the ﬁnal
logistic regression models. It is important to note that these
results describe associations between certain infection pre-
vention and control policies and prevalence of AROs, and do
not necessarily imply a causal relationship. Moreover, we
were unable to audit actual practice or policy implementa-
tion. However, these ﬁndings are consistent with those of
others suggesting that implementation of certain infection
control interventions may lead to lower prevalence of AROs
[25–27].
We believe that the results of this study are representative
of Canadian adult acute-care hospitals with at least 50 inpatient
beds, as two-thirds of all eligible hospitals from all 10 provinces
participated, with characteristics similar to those of nonpar-
ticipating facilities. Moreover, 75% of hospitals that responded
to the 2010 survey also participated in 2012, allowing for an
analysis of trends in prevalence over time. These results are not
applicable to pediatric hospitals or to rehabilitation, psychiatric
or long-term care facilities. Detection bias and sampling varia-
tion may have affected the identiﬁcation of colonized patients asand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 553–559
558 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIscreening practices varied, particularly for resistant Gram-
negative organisms.
In summary, the prevalence of ARO infections in Canadian
hospitals was relatively low, and remained stable between 2010
and 2012. However, the prevalence of VRE colonization
increased between 2010 and 2012, despite a decrease in the use
of active surveillance and of additional infection control pre-
cautions for patients with VRE. This study also provides the ﬁrst
national prevalence rates for ESBLs and CREs. Ongoing national
surveillance for AROs is essential to monitor changes in the
burden of disease associated with these organisms over time
and to determine the effects of various interventions.Variable
MRSA Colonization/Infection MRSA Infection VRE Colonization /Infection Clostridium difﬁcile Infection
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Hospital size >200 beds 0.84 (0.74-0.95) 0.005 0.82 (0.60-1.12) 0.21 1.94 (1.60-2.35) <0.001 1.67 (1.30-2.15) <0.001
Occupancy rate 1.00 (0.99-1.01) 0.11 1.01 (0.99-1.02) 0.27 1.00 (0.99-1.01) 0.33 1.01 (1.00-1.02) 0.05
Teaching hospital 1.06 (0.95-1.87) 0.29 0.98 (0.74-1.31) 0.91 1.39 (1.20-1.60) <0.001 1.27 (1.05-1.55) 0.02
No. FTE ICP/100 beds* 1.25 (1.14-1.37) <0.001 1.24 (0.98-1.57) 0.07 0.58 (0.50-0.67) <0.001 0.97 (0.81-1.16) 0.73
Hemodialysis 0.91 (0.80-1.03) 0.14 1.01 (0.73-1.41) 0.94 1.35 (1.13-1.62) <0.001 1.24 (0.97-1.57) 0.08
Bone marrow transplant 1.17 (1.02-1.34) 0.03 1.48 (1.06-20.59) 0.02 1.19 (0.99-1.42) 0.06 1.17 (0.92-1.50) 0.09
Solid organ transplant 1.00 (0.87-1.17) 0.92 1.11 (0.76-1.62) 0.85 1.21 (1.01-1.46) 0.04 1.24 (0.97-1.60) 0.09
Pediatrics unit 0.72 (0.64-0.80) <0.001 0.96 (0.72-1.29) 0.81 0.62 (0.53-0.71) <0.001 0.80 (0.66-0.98) 0.03
Burn unit 1.01 (0.87-1.17) 0.88 1.16 (0.81-1.67) 0.43 0.61 (0.49-0.76) <0.001 0.74 (0.56-0.99) 0.05
Cardiac surgery 1.14 (1.00-1.29) 0.05 1.01 (0.73-1.41) 0.94 1.55 (1.33-1.80) <0.001 1.38 (1.12-1.70) 0.003
Neurosurgery 0.96 (0.85-1.09) 0.54 0.95 (0.70-1.30) 0.75 1.68 (1.45-1.94) <0.001 1.14 (0.93-1.40) 0.22
Hand hygiene audits 0.82 (0.63-1.07) 0.14 1.94 (0.72-5.23) 0.19 1.07 (0.73-1.57) 0.73 1.62 (0.86-1.30) 0.14
Hand hygiene compliance > 80% 0.81 (0.72-0.91) <0.001 0.82 (0.61-1.11) 0.20 1.18 (1.01-1.39) 0.04 0.77 (0.63-0.95) 0.001
Routine use of a private room 0.57 (0.51-0.64) <0.001 0.39 (0.28-0.55) <0.001 0.52 (0.45-0.61) <0.001 0.98 (0.80-1.21) 0.89
Targeted vs universal admission
screening
0.82 (0.73-0.92) <0.001 1.21 (0.89-1.64) 0.22 0.96 (0.82-1.12) 0.61
Periodic prevalence screening of
inpatient units
1.16 (1.04-1.29) 0.01 0.82 (0.61-1.09) 0.17 1.16 (1.00-1.34) 0.05
Enhanced environmental cleaning 0.78 (0.70-0.87) <0.001 0.98 (0.73-1.30) 0.87 1.26 (1.05-1.52) 0.01
Routine use of antiseptic soap for
patient bathing/washing
1.03 (0.91-1.16) 0.67 1.10 (0.81-1.50) 0.53 0.72 (0.57-0.89) 0.003
Routine use of a surgical mask
(for MRSA)
0.61 (0.52-0.71) <0.001 0.76 (0.52-1.10) 0.14
Routine MRSA decolonization 0.58 (0.50-0.69) <0.001 0.57 (0.37-0.88) 0.01
PCR testing for C. difﬁcile 1.41 (1.15-1.73) 0.001
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